1. Clinical Overview
A fixed-dose combination (FDC) of three distinct pharmacological agents designed for comprehensive secondary prevention of atherothrombotic cardiovascular events. Aspirin is a non-selective, irreversible cyclooxygenase (COX) inhibitor with antiplatelet effects. Rosuvastatin is a synthetic, competitive HMG-CoA reductase inhibitor (statin) for lipid management. Clopidogrel is a thienopyridine prodrug that irreversibly inhibits the P2Y12 subtype of ADP receptor on platelets. This combination is specifically indicated for patients with established cardiovascular disease (e.g., post-MI, post-stroke, or with established PAD) requiring intensive secondary prevention.
| Onset | Duration | Bioavailability |
|---|---|---|
| Aspirin: 20-30 minutes (antiplatelet); Rosuvastatin: LDL-C reduction begins in 1 week, maximal in 4 weeks; Clopidogrel: Active metabolite peaks in ~1 hour, but full antiplatelet effect may take 3-7 days with a loading dose. | Aspirin: 7-10 days (life of platelet); Rosuvastatin: ~20 hours; Clopidogrel: 5-7 days (life of platelet). | Aspirin: ~50% (rapidly hydrolyzed to salicylate); Rosuvastatin: ~20%; Clopidogrel: >50% (but extensive metabolism to active form required). |
2. Mechanism of Action
This combination exerts a multi-pronged attack on the pathophysiology of atherothrombosis. Aspirin irreversibly acetylates serine residue 529 of platelet cyclooxygenase-1 (COX-1), inhibiting thromboxane A2 (TXA2) synthesis, a potent platelet aggregator and vasoconstrictor. Clopidogrel, after bioactivation, irreversibly blocks the P2Y12 subtype of the ADP receptor on the platelet surface, inhibiting ADP-mediated platelet activation and aggregation. This dual antiplatelet therapy (DAPT) provides synergistic inhibition of platelet aggregation. Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL-cholesterol from the bloodstream. It also exerts pleiotropic effects including plaque stabilization, improved endothelial function, and anti-inflammatory actions.
3. Indications & Uses
- Secondary prevention of atherothrombotic events in patients with established Coronary Artery Disease (CAD) including post-Myocardial Infarction (MI)
- Secondary prevention in patients with established Cerebrovascular Disease (e.g., post-Ischemic Stroke or Transient Ischemic Attack (TIA))
- Secondary prevention in patients with symptomatic Peripheral Arterial Disease (PAD)
4. Dosage & Administration
Adult Dosage: One tablet (Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg) orally once daily. Usually taken in the evening for rosuvastatin (though timing is not critical).
Administration: Take with or without food. Swallow whole with a glass of water. Do not crush or chew. To minimize GI upset from aspirin, it can be taken with food. Rosuvastatin can be taken at any time of day, with or without food. If a dose is missed, take it as soon as remembered. If it is near the time for the next dose, skip the missed dose. Do not double the dose.
5. Side Effects
Common side effects may include:
- Headache
- Dyspepsia, nausea, abdominal pain
- Constipation or diarrhea
- Myalgia (muscle pain)
- Epistaxis (nosebleeds)
- Easy bruising
- Increased liver enzymes (asymptomatic)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Warfarin, NOACs (Apixaban, Rivaroxaban, etc.) | Profoundly increased risk of major and fatal bleeding. | Contraindicated / High |
| Other NSAIDs (Ibuprofen, Diclofenac) | Increased GI bleeding risk; may antagonize antiplatelet effect of aspirin. | High |
| Proton Pump Inhibitors (especially Omeprazole, Esomeprazole) | May reduce antiplatelet effect of clopidogrel by inhibiting CYP2C19. | Moderate (Pantoprazole preferred if needed) |
| Fluconazole, Voriconazole | Inhibit CYP2C19, may reduce clopidogrel activation. | Moderate |
| Rifampicin | Induces CYP2C19/CYP3A4, may increase clopidogrel activation but also metabolism. | Moderate |
| Gemfibrozil, Fenofibrate | Increased risk of myopathy/rhabdomyolysis with rosuvastatin. | High (Fenofibrate is safer combination if needed) |
| Cyclosporine | Significantly increases rosuvastatin exposure; contraindicated. | High |
| Methotrexate | Aspirin reduces renal clearance of methotrexate, leading to severe toxicity. | High |
| SSRIs (e.g., Sertraline, Escitalopram) | Increased bleeding risk due to impaired platelet serotonin uptake. | Moderate |
| Systemic corticosteroids | Increased GI bleeding risk. | Moderate |
7. Patient Counselling
- DO take the medicine exactly as prescribed, at the same time each day.
- DO inform all your doctors and dentists about this medication before any procedure or new prescription.
- DO report any unusual bleeding (gums, nose, heavy menstrual), black/tarry stools, or red urine.
- DO have regular blood tests (lipid profile, LFT, renal function) as advised.
- DONT stop taking this medicine without consulting your cardiologist/physician. Sudden stoppage can increase heart attack/stroke risk.
- DONT take other painkillers (like Ibuprofen, Diclofenac) without asking your doctor.
- DONT consume alcohol excessively.
8. Toxicology & Storage
Overdose: Aspirin: Tinnitus, vertigo, headache, confusion, hyperventilation, fever, sweating, nausea/vomiting, metabolic acidosis, respiratory alkalosis, coma, cardiovascular collapse. Clopidogrel: Bleeding complications. Rosuvastatin: Elevated transaminases, possible severe myopathy.
Storage: Store below 30°C in a cool, dry place, protected from light and moisture. Keep in the original blister pack or container. Keep out of reach of children.